Aspen Pharmacare Holdings Limited announced that it has concluded an agreement with Acino Pharma AG in terms of which Acino will acquire a product portfolio of six products for a consideration of approximately ZAR 1.8 billion, plus the cost of the related inventory ("the Transaction"). The products included in the Transaction are sold under the brand names, Altosec, Aspen Granisetron, Ciavor, Grantryl, Trustan and Zuvamor in South Africa and recorded revenue of ZAR 512 million in the financial year ended 30 June 2021. The Transaction will be conditional upon the fulfilment of customary conditions precedent applicable to transactions of this nature. It is anticipated that the Transaction will complete by 31 December 2021. Aspen and Acino will enter into a Manufacturing and Supply Agreement in terms of which Aspen will supply the Aspen manufactured products to Acino for 7 years. The Transaction forms part of Aspen's communicated strategy to refine its product portfolio in South Africa. The proceeds from the Transaction will be used to reduce the Group's debt.